EULAR responses of patients with psoriatic arthritis at Months 3 and 6. Patients are classified by low-affinity and high-affinity FCGR2A genotype and stratified by type of TNF blocker.
| FCGR2A, n (%) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Infliximab or Adalimumab, n = 48 | Etanercept, n = 55 | |||||||
| EULAR Response | HH + HR (High affinity) | RR (Low affinity) | Total | p* | HH + HR (High affinity) | RR (Low affinity) | Total | p* |
| 3 months | ||||||||
| None | 5 (13) | 1 (10) | 6 (13) | 5 (12) | 4 (33) | 9 (16) | ||
| Moderate + Good | 33 (87) | 9 (90) | 42 (88) | 1.000 | 38 (88) | 8 (67) | 46 (84) | 0.092 |
| 6 months | ||||||||
| None | 4 (11) | 2 (20) | 6 (13) | 3 (7) | 4 (33) | 7 (13) | ||
| Moderate + Good | 34 (89) | 8 (80) | 42 (88) | 0.591 | 40 (93) | 8 (67) | 48 (87) | 0.034 |
↵* Fisher’s exact test. Pairwise comparison significance level < 0.025. EULAR: European League Against Rheumatism; TNF: tumor necrosis factor.